Please read and agree to the terms and conditions of this site.
@xconomy.com 15 days ago
UCSD, 5 Diagnostic Makers Partner to Ramp COVID-19 Testing Capacity
@xconomy.com 29 days ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 1 month ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com 1 month ago
Early Bird Sale Ending for San Diego’s Xcelerating Life Sciences Conference
@xconomy.com 2 months ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com 2 months ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com 2 months ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com 5 months ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com 5 months ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com 5 months ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com 6 months ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com 6 months ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com 6 months ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com 6 months ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com 6 months ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com 6 months ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com 7 months ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 7 months ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com 7 months ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com 7 months ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com 8 months ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com 8 months ago
White House Floats Canadian Import Plan But Excludes Many Costly Drugs
@xconomy.com 8 months ago
Spine-Surgery Medtech Startup Carlsmed Merges With Imaging Company
@xconomy.com 8 months ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com 9 months ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com 9 months ago
Acutus, Maker of Next-Gen Electrophysiology Tech, Adds $100M Series D
@xconomy.com 9 months ago
Review: Inside the House of Lies at Theranos
@xconomy.com 9 months ago
Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer
@xconomy.com 10 months ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com 10 months ago
California Life Sciences Fueled by Education, Established Companies
@xconomy.com 10 months ago
San Diego Life Sciences Roundup: MedCrypt, LunaDNA, Dynacure & More
@xconomy.com 10 months ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com 11 months ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com 11 months ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com 11 months ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com 11 months ago
Meet the Xconomy Awards San Diego Digital Trailblazer Finalists
@xconomy.com 11 months ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com 11 months ago
Roswell, Organovo & More: Xconomy Awards Innovation at the Intersection Finalists
@xconomy.com 11 months ago
Censinet Takes Off With $7.8M to Track Cyber Risks in Healthcare
@xconomy.com 11 months ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com 1 year ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com 1 year ago
Biolinq Adds $4.75M to Advance Glucose Monitoring Biosensor Patch
@xconomy.com 1 year ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com 1 year ago
Corza Health Emerges Led by Former NuVasive, GreatCall Executives
@xconomy.com 1 year ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com 1 year ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com 1 year ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com 1 year ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More